One phase II trial evaluating icotinib (a first-generation EGFR TKI), for 4–8 months, after platinum-based adjuvant chemotherapy, in resected NSCLC EGFR mutant stage IB-II-IIIA showed no significant increase in the proportion of disease-free patients (90.5% vs. 66.7%, p = 0.06) compared to observation alone [49]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.